ZBH Stock Chart & Stats
$1502.00
$0.00(0.00%)
At close: 4:00 PM EDT
$1502.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1,368.51 - $2,145.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$323.07B
Enterprise Value$24.76K
Total Cash (Recent Filing)$424.20M
Total Debt (Recent Filing)$7.47B
Price to Earnings (P/E)24.7
Beta<0.01
Next Earnings
Aug 05, 2026EPS Estimate
35.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.87
Shares Outstanding193,462,480
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.26
Price to Book (P/B)1.40
Price to Sales (P/S)2.16
P/FCF Ratio12.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,727.41Price Target Upside15.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)148.04
Revenue Forecast (FY)$149.12B
Bulls Say, Bears Say
Bulls Say
High Margins & Cash GenerationSustained high gross and EBITDA margins indicate structural cost and pricing advantages in orthopedic implants. Free cash flow exceeding net income and sizeable TTM FCF provide durable internal funding for R&D, robotics rollout, buybacks, and debt reduction, supporting strategic flexibility over the next 2–6 months.
Robotics And Tech MomentumAccelerating adoption of robotics, software and related consumables creates a structural revenue stream beyond implants. Completed Monogram enrollment and strong TMINI/ROSA uptake support near‑term commercialization and build recurring procedure-related revenue, enhancing differentiation and long-term market share potential.
Expanded LiquidityProactive refinancing with multi‑year and short‑term revolvers meaningfully strengthens the company’s liquidity profile and preserves flexibility for acquisitions, working capital and opportunistic debt paydown. This reduces refinancing risk and supports strategic execution during commercial transition.
Bears Say
Compressed Returns And MarginsDeclining ROE and compressed net margins signal the equity base is generating less profit, reducing capital efficiency. Over 2–6 months this limits capacity to fund growth organically and undermines shareholder returns unless operating leverage or pricing recovers, making capital allocation decisions more constrained.
Commercial Transformation DisruptionThe U.S. salesforce transformation and international go‑to‑market changes are ongoing through 2027 and have already caused account losses and order timing issues. Execution risk and elevated commercial investments can depress growth and pressure margins until the new model proves consistently productive across territories.
Price Erosion & Higher Financing CostsStructural pricing pressure of up to 100 basis points and higher interest expense tied to acquisition debt both erode net income and FCF margins. Combined, they create durable headwinds to profitability and cash conversion that can persist across multiple quarters absent margin offsets or deleveraging.
Zimmer Biomet Holdings News
ZBH FAQ
What was Zimmer Biomet Holdings’s price range in the past 12 months?
Zimmer Biomet Holdings lowest stock price was $1368.51 and its highest was $2145.00 in the past 12 months.
What is Zimmer Biomet Holdings’s market cap?
Zimmer Biomet Holdings’s market cap is $323.07B.
When is Zimmer Biomet Holdings’s upcoming earnings report date?
Zimmer Biomet Holdings’s upcoming earnings report date is Aug 05, 2026 which is in 5 days.
How were Zimmer Biomet Holdings’s earnings last quarter?
Zimmer Biomet Holdings released its earnings results on Apr 28, 2026. The company reported $36.451 earnings per share for the quarter, beating the consensus estimate of $32.526 by $3.924.
Is Zimmer Biomet Holdings overvalued?
According to Wall Street analysts Zimmer Biomet Holdings’s price is currently Undervalued.
Does Zimmer Biomet Holdings pay dividends?
Zimmer Biomet Holdings does not currently pay dividends.
What is Zimmer Biomet Holdings’s EPS estimate?
Zimmer Biomet Holdings’s EPS estimate is 35.06.
How many shares outstanding does Zimmer Biomet Holdings have?
Zimmer Biomet Holdings has 193,462,480 shares outstanding.
What happened to Zimmer Biomet Holdings’s price movement after its last earnings report?
Zimmer Biomet Holdings reported an EPS of $36.451 in its last earnings report, beating expectations of $32.526. Following the earnings report the stock price went down -10.712%.
Which hedge fund is a major shareholder of Zimmer Biomet Holdings?
Currently, no hedge funds are holding shares in MX:ZBH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zimmer Biomet Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1,727.41 (15.01% Upside)
$1,727.41 (15.01% Upside)
Blogger Sentiment
Bullish
MX:ZBH Sentiment 80%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $7.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.70%
12-Months-Change
Fundamentals
Return on Equity
1.06%
Trailing 12-Months
Asset Growth
2.42%
Trailing 12-Months
Company Description
Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.
ZBH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented more positive developments than negative ones: solid top‑line growth (reported and organic), an EPS beat and raised EPS and free cash flow guidance, strong cash generation, accelerating performance from strategic acquisitions (Paragon 28) and clear momentum in technology and robotics (Monogram enrollment complete, ROSA/TMINI adoption). Offsetting items include short‑term disruption from the U.S. salesforce transformation and legacy knee transitions, some international go‑to‑market disruption, a one‑time tariff benefit that partially pulled forward upside, and higher interest expense tied to acquisition debt. On balance the company appears to be executing on its strategic priorities while managing expected transitional headwinds.View all MX:ZBH earnings summariesZBH Net sales Breakdown
40.36% Knees
25.43% Hips
26.12% S.E.T
8.09% Technology & Data, Bone Cement and Surgical
ZBH Stock 12 Month Forecast
Average Price Target
$1,727.41
▲(15.01% Upside)